CRDF News and Press, Cardiff Oncology Inc. From 12/15/21

Cardiff has one asset, onvansertib, a PLK1 inhibitor which has performed well in the clinic thus far in second line KRAS-mutated mCRC. Pfizer made a recent $15m investment and will get a first look at data. The response rate looks promising to date but the data is not yet mature. ...

Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium PR Newswire SAN DIEGO , Dec. 10, 2021 /PRNewswire/ -- Cardiff Oncology,...

Energy Focus (NASDAQ:EFOI) +52% launches nUVo virus-targeted UVC air disinfectors to public. Lexaria Bioscience (NASDAQ:LEXX) +25% dehydraTECHTM-CBD reduces arterial stiffness, results confirmed in human clinical study HYPER-H21-2. Dare Bioscience (NASDAQ:DARE) +23% announces F...

Cardiff Oncology (CRDF -4.9%) granted non-qualified stock option awards on Dec.2 to purchase 200,112 shares of its common stock to two new employees. The options have an exercise price of $5.46/share; each option will vest over a 4-year period, with 25% of the shares ...

Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , Dec. 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options...

The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. Four emerging trends back up this assertion. First, Pfizer (NYSE: PFE) and Moderna are both flush with cash thanks to their novel coronavirus vaccines...

Cardiff Oncology (NASDAQ: CRDF) , a clinical-stage oncology company, saw its shares climb more than 15% early Thursday. The stock closed at $5.23 on Wednesday, then opened at $6.03 on Thursday before climbing to as high as $6.29. As of 1:35 p.m. ET, it was trading up by 10.1% at $5....

Dicerna Pharmaceuticals DRNA +78% Novo Nordisk agrees to acquire Dicerna for more than $3 billion Cardiff Oncology (NASDAQ:CRDF) +23% announces $15M equity investment from Pfizer through its Pfizer breakthrough growth initiative Cloopen Group Holding RAAS +19% on Q3 result...

Cardiff Oncology (NASDAQ:CRDF) soars 26.8% premarket after Pfizer (NYSE:PFE) made a $15M equity investment in the company as part of its Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. Pursuant to a securities purchase agreement...

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative - Pfizer invests $15 million in Cardiff Oncology common shares - Adam Schayowitz, Ph.D., MBA, Vice President, Medicine Team Group Lead for Breast Cancer, Co...